EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update
Annals of the Rheumatic Diseases (ARD)
is a leading rheumatology journal from EULAR, publishing original research, reviews and recommendations
Impact Factor: 20.3
Citescore: 35
All metrics >>
Latest EULAR Recommendations
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update
Authors
Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
The Author Information section provides general guidelines and requirements for specific article types.
Information is also provided on editorial policies and open access.
Latest Articles
Rheumatoid arthritis:
Rheumatoid arthritis patients harbour aberrant enteric bacteriophages with autoimmunity-provoking potential: a paired sibling study31 July 2024
Early arthritis:
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial31 July 2024
IgG4 related disease:
Multiorgan involvement and circulating IgG1 predict hypocomplementaemia in IgG4-related disease31 July 2024
Recommendations
The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.
All EULAR recommendations are free to access.
Each recommendation also has an accompanying lay summary, which is also free to access.
Video Abstract
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials
Discussion: Type I IFN blockade with anifrolumab modulated multiple inflammatory pathways downstream of type I IFN signalling, including apoptotic, innate and adaptive mechanisms that play key roles in SLE immunopathogenesis.
Find out moreAltmetrics
Jobs
Carmarthen
We are seeking to appoint an enthusiastic and motivated Specialty Doctor in Anaesthetics to support Anaesthesia provisionRecruiter: Hywel Dda University Health Board
Consultant Anaesthetist
Grampian
NHS Grampian is delighted at the prospect of expanding the Anaesthetic DepartmentRecruiter: NHS Grampian
Salaried GP
York, North Yorkshire
Salaried GP positions available within our York and Scarborough teams. Excellent opportunity to progress through to PartnershipRecruiter: Haxby Group Practice
Salaried GP Vacancy
Wilton, Salisbury
The Orchard Partnership combines the best of traditional general practice with patient centred innovation.Recruiter: Old Orchard Partnership
Consultant Forensic Psychiatrist
Berkshire
This is an exciting opportunity to work as a Consultant Forensic Psychiatrist in Broadmoor Hospital.Recruiter: West London NHS Trust